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Abstract. Placentation requires the production of numerous 
growth factors, hormones and transcription factors. Many of 
them, like the adipose tissue-derived leptin or adiponectin, 
have been identified in the placenta and their role has been 
established in the proliferation and subsequent development of 
the placenta. Apelin is another adipokine known for prolifera-
tive effects in different cell types. PcR, immunoblotting and 
immunocytochemistry were used to study mRNA and protein 
expression of apelin and its receptor (APJ) in syncytiotro-
phoblast (BeWo) and cytotrophoblast (JEG-3) cells as well in 
immunohistochemistry in human normal placenta slides. The 
effect of apelin on cell proliferation study was investigated by 
alamarBlue® and cell counting Kit-8 assays, the cell cycle 
by the flow cytometry method and the protein expression of 
cyclins and phosphorylation level of extracellular signal-regu-
lated kinases (ERK)1/2, phosphatidylinositol 3'-kinase/protein 
kinase B (Akt), signal transducer and activator of transcrip-
tion 3 (Stat3) and 5'-monophosphate-activated protein kinase 
(AMPKα) were studied by western blotting. Apelin was 
increased in JEG-3 compared with in BeWo cells, while APJ 
was the same in both placenta cell lines. Immunocytochemical 
analyses revealed high cytoplasmic and/or membrane apelin 
localisation in JEG-3, while BeWo cells exhibited markedly 
weaker apelin signal in the cytoplasm. Apelin increased 
cell proliferation as well as the percentage of cells in the 
G2/M phase of the cell cycle, cyclin proteins and the expres-
sion of all kinases mentioned above. In conclusion, apelin by 
promotion of trophoblast cell proliferation by APJ and ERK1/2, 
Stat3 and AMPKα signalling could be a new important adipo-
kine in the regulation of early placental development.
Introduction
Placentation is a dynamic and complicated process. After 
implantation, trophoblasts differentiate into cyto- and 
syncytio-trophoblast cells, and proliferate much more rapidly 
than embryo cells, creating an organ in just a few weeks that 
properly fulfils its function and supports foetus develop-
ment (1). Any abnormalities in formation and function of the 
placenta may have serious consequences in foetal life, like 
intrauterine growth restriction (IUGR) (2), preeclampsia (3), 
miscarriage (4), as well as long-term complications like 
cardiovascular (5) and chronic diseases in adulthood (6). 
Placentation requires the production of growth factors, adhe-
sion proteins, hormones and transcription factors. Numerous 
factors have been identified in placenta cells and their role 
has been established in implantation and subsequent develop-
ment of the placenta (1,7). For example, insulin-like growth 
factors 1 (IGF1) and IGF2 stimulate cytotrophoblast prolifera-
tion and decreased cell apoptosis (8), while leptin promotes 
trophoblast cell proliferation, survival and invasion (9-11). 
Moreover, adiponectin has antiproliferative effect in placenta 
cell lines JEG-3 and BeWo (12).
Apelin is another newly discovered adipokine. In addition 
to adipose tissue, it is expressed in other tissues like lung, 
kidney, ovary, heart, brain and blood vessels (13,14). Produced 
as a 77-amino acid prepropeptide, it is enzymatically cleaved 
into smaller fragments of 12, 17 and 36 amino acids in length 
and a 13-amino acid pyroglutamylated peptide that has the 
strongest physiological effect (15). Of the numerous processes 
in which apelin is involved, it primarily regulates fluid homeo-
stasis (16), energy metabolism (17), blood pressure (18) and 
angiogenesis (19). Its actions are mediated by the APJ receptor, 
a transmembrane receptor associated with a G protein (20). 
Previous data identified the apelinergic (apelin/apelin 
receptor APJ) system in cytotrophoblast, syncytiotrophoblast 
and foetal endothelial cells (3), where it was demonstrated 
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that the dominant form in the placental villi is pyr-apelin-13 
and apelin-13 (21). In mice, an APJ defect leads to embryo 
lethality due to significant growth retardation and vascular 
deformations (22). Studies on rat models showed that in normal 
pregnancies, the level of apelin in the maternal serum is elevated 
in the early stages of pregnancy, after which it drops by 50% in 
late pregnancy. These changes are caused by the increased 
clearance of apelin by the gain of activity of the Ang-converting 
enzyme-related carboxypeptidase-2 (AcE2), which hydrolyses 
apelin (23). Moreover, during the increase of apelin in the 
maternal serum, the placenta releases significant amounts of 
AcE2 (24). Nevertheless, higher foetal apelin concentrations 
suggest a potential role in foetal growth and ex utero angiogen-
esis (25). Numerous studies focus on the role of the apelin in 
the pathophysiology of preeclampsia and in IUGR (6,21,26); 
however, the action of apelin on trophoblastic cell function, such 
as proliferation and cell cycle, is still unknown.
Published data led the present study to hypothesise that 
apelin and APJ can regulate the placenta formation process 
by action on placental cell proliferation. To verify this 
hypothesis, two placental cell lines reflecting both syncy-
tiotrophoblast (BeWo) and cytotrophoblast (JEG-3) cells 
were used. First, the mRNA and protein expression as 
well as immunolocalisation of the apelinergic system in 
both cell lines were measured. Moreover, human placenta 
slides were used to confirm apelin and APJ positive immu-
nolocalisation. Next, the effect of human recombinant 
apelin-13 on the placental cell proliferation, cell cycle and 
cyclins d, E, A and B protein expression were analysed. As for 
the molecular mechanism by which apelin regulates prolifera-
tion, the activation of different kinases such as extracellular 
signal-regulated kinases 1/2 (ERK1/2), phosphatidylinositol 
3'-kinase/protein kinase B (Akt), 5'-monophosphate-activated 
protein kinase α (AMPKα) and signal transducer and activator 
of transcription 3 (Stat3) was studied. Kinases PI3K/Akt, 
ERK1/2, AMPKα and JAK/Stat3 are signalling molecules 
involved in most types of cell growth, proliferation, survival 
and apoptosis (27-29) and in the major molecular mechanism 
of apelin action in other cell types (30-32).
Materials and methods
Reagents. Phosphate buffered saline (PBS), dMEM/F12 
medium and trypsin were purchased from Gibco; Thermo Fisher 
Scientific, Inc. Insulin, glycerol, EdTA, dithiothreitol, 
3,3'-diaminobenzidine (dAB), bromophenol blue, sodium 
deoxycholate, Nonidet P-40 (NP-40), Tween-20, Pd098059, 
AG490 and apelin-13 (cat. no. A6469) were obtained from 
Sigma-Aldrich; Merck KGaA. Foetal bovine serum (FBS; heat 
inactivated) was purchased from Biowest. Tris base, SdS and 
bovine serum albumin (BSA) were purchased from Bioshop 
(canada, Inc.). ML221, LY294002 and compound c were 
obtained from Tocris Bioscience, cell Signaling Technology, Inc. 
and Merck KGaA, respectively. The WesternBright™ Sirius kit 
was purchased from Advansta, Inc. Bradford protein assay kit, 
4-20% gels (cat. no. 456-1093) and membranes (cat. no. 1704156) 
were obtained from Bio-Rad Laboratories, Inc.
Cell culture and treatment. Syncytiotrophoblast BeWo 
(cat. no. CCL‑98) and cytotrophoblast JEG‑3 (cat. no. HTB‑36) 
cell lines were obtained from the American Type culture 
collection. BeWo cells were cultured in dMEM/F12 medium 
without phenol red, supplemented with 0.01 mg/ml insulin and 
10% FBS, while JEG-3 cells were cultured in dMEM/F12 
medium without phenol red, supplemented only with 10% FBS. 
cell lines were grown in 75-cm2 tissue culture flasks in a 37˚C 
incubator with a humidified mixture of 5% CO2 and 95% air.
Treatment 1. The aim of this experiment was to analyse mRNA 
and protein expression of apelin and APJ, as well as immu-
nolocalisation. JEG-3 or BeWo cells (1x104 cells/96-well) 
were cultured in dMEM/F12 with 5% FBS for 24 h and then 
cells were carefully rinsed with PBS and stored in ‑70˚C for 
mRNA expression analysis, or lysed in ice-cold lysis buffer 
including 50 mM Tris‑HCl (pH 7.5) containing 100 mM 
Nacl, 0.5% sodium deoxycholate, 0.5% NP-40, 0.5% SdS and 
protease inhibitors and stored at ‑20˚C for protein expression 
analysis. Immunofluorescence labelling was performed on 
JEG-3 or BeWo cells, seeding at 2x104 cells/4-well labtech 
(Bd Biosciences; Becton, dickinson and company) cultured 
in dMEM/F12 with 5% FBS for 24 h. Then cells were rinsed 
with PBS and fixed using absolute methanol for 40 min at 20˚C.
Treatment 2. In this experiment the effect of human recombi-
nant apelin-13 on cell proliferation and cyclins d, E, A and B 
protein expression was focused on examine. JEG-3 or BeWo 
cells (4x103 cells/per well of 96-well plate) were cultured 
in dMEM/F12 with 10% FBS for 24 h. Next, media were 
replaced by dMEM/F12 with 1% FBS and cells were treated 
for 24, 48 and 72 h with apelin at doses 0.02, 0.2, 2.0, 20 and 
200 ng/ml. The concentrations of apelin were chosen based on 
the authors' preliminary research and previous study (33). The 
alamarBlue stock solution or cell counting Kit-8 (ccK-8) 
reagent in amounts equal to 10% of the incubation volume 
was added, according to the manufacturers' protocol. BeWo 
cells (4x103 cells/per well of 96-well plate) were cultured with 
apelin at doses 2 and 20 ng/ml for 24, 48 and 72 h, then cells 
were lysed in ice‑cold lysis buffer and stored at ‑20˚C for 
cyclin protein expression analysis.
Treatment 3. The aim of this experiment was to examine 
the effect of human recombinant apelin-13 on the cell cycle. 
JEG-3 or BeWo cells (2.5x104 cells/per 24-well plate) were 
cultured in dMEM/F12 with 10% FBS for 24 h. Then, media 
were replaced by dMEM/F12 with 1% FBS and cells were 
incubated for 24, 48 and 72 h with 2 ng/ml of apelin. Both 
trophoblastic cells were harvested by trypsinisation and 
washed in PBS. Then, cells were fixed with 70% cold ethanol 
at 4˚C for 60 min and stored at ‑20˚C. These cells were used for 
measuring the percentage of the total cell population in each 
phase of the cell cycle.
Treatment 4. The aim of this experiment was to examine 
the molecular mechanism of the apelin action on BeWo cell 
proliferation. After 24 h, media were replaced by dMEM/F12 
with 1% FBS and cells were treated with apelin at 2 ng/ml 
for 1, 5, 15, 30, 45, 60 and 90 min. Then, cells were lysed in 
ice‑cold lysis buffer and stored at ‑20˚C for protein expres-
sion of kinases phosphorylated p-ERK1/2, total ERK, p-Akt, 
total Akt, p-Stat3, total-Stat3, p-AMPKα and total AMPKα 
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study. To test the activation of kinases in different signalling 
pathways, cells were pre-treated with selective inhibitors of 
ERK1/2, Akt, Stat3 and AMPKα kinases (Pd98059 at 10 µM, 
LY294002 at 10 µM, AG490 at 50 µM and compound c at 
10 µM, respectively), as well as with the inhibitor of APJ 
(ML221 at 10 µM) for 1 h, and then apelin at 2 ng/ml was 
added. The concentrations of inhibitors were chosen based on 
the authors' preliminary research and previous study (33). The 
alamarBlue stock solution was added to the wells in amounts 
equal to 10% of the incubation volume to measurement cell 
proliferation after 72 h of culture.
Real time PCR. Total RNA isolation and cdNA synthesis 
(for 1 h at 37˚C) were carried out on cells at the baseline 
using the TaqMan Gene Expression cells-to-cT kit (Applied 
Biosystems; Thermo Fisher Scientific, Inc.), following the 
manufacturer's protocol. The resulting preamplified cDNA 
preparations were analysed by quantitative PcR using the 
StepOnePlus Real-Time PcR System (Applied Biosystems; 
Thermo Fisher Scientific, Inc.) and TaqMan Gene Expression 
Assays for apelin (cat. no. Hs00936329_m1; RefSeq 
NM_017413.4) and APJ (cat. no. Hs00270873_s1; RefSeq 
NM_005161.4) (Applied Biosystems; Thermo Fisher Scientific, 
Inc.), in combination with TaqMan Gene Expression Master 
Mix containing ROX reference dye (Applied Biosystems; 
Thermo Fisher Scientific, Inc.). The thermal cycling conditions 
were as follows: 50˚C for 2 min, 95˚C for 10 min and then 
40 cycles of 95˚C for 15 sec and 60˚C for 60 sec. Duplicate 
control samples lacking cdNA were prepared for each gene 
and showed no dNA contamination. The gene expression was 
normalized using the geometric mean of three housekeeping 
genes: GAPDH (cat. no. 4310884E; RefSeq NM_002046.3), 
TBP (cat. no. Hs00920495_m1; RefSeq NM_001172085.1), 
YWHAZ (cat. no. Hs01122445_g1; RefSeq NM_001135699.1) 
the expression of which was stable under these conditions (data 
not shown). 3T3L1 adipose tissue cells [culture of cells was 
described (34)] and ovarian follicles cells [isolation and culture 
of cells were described previously (33)] were used as a positive 
control to study apelin/APJ expression in the placenta. The 
normalized values for relative expression (R) were calculated 
according to the following equation: R=(EGene-cq Gene)/(geometric 
mean (EGAPDH‑Cq GAPDH; ETBP-cq TBP; EYWHAZ‑Cq YWHAZ), where 
Cq was the cycle threshold and E was the PCR efficiency for 
each primer pair (35).
Western blotting. The western blotting procedure used to 
determine apelin/APJ, cyclins and kinases proteins expression 
was described previously (33). Briefly, the proteins (80 µg) 
were separated by 4-20% Mini-Protean TGX System Precast 
Protein Gels and transferred to Trans-Blot Turbo Mini PVdF 
Transfer Packs (Bio-Rad Laboratories, Inc.). The membranes 
were blocked for 1 h in 0.02 M Tris-buffered saline containing 
5% BSA and 0.1% Tween-20 at room temperature (RT), then 
incubated overnight at 4˚C with appropriate primary antibodies 
(Table I). The membranes were then washed in Tris-buffered 
saline containing 0.1% Tween-20 and incubated for 1 h at RT 
with a horseradish peroxidase-conjugated secondary antibody 
(Table I). β-actin was used as a loading control. Signals were 
detected by chemiluminescence using a WesternBright™Sirius 
(cat. no. K-12043-d20; Advansta, Inc.) and visualised using 
the chemidoc™ XRS+ System (Bio-Rad Laboratories, Inc.). 
All bands were quantified using a densitometer and ImageJ 
software (version 1.51; US National Institutes of Health).
Immunocytochemistry. After fixation, placenta cells were 
incubated for 5 min with 0.2% Triton in PBS. Next, nonspe-
cific binding sites were blocked with 3% BSA for 3 h at RT. 
Thereafter, cells were incubated overnight at 4˚C in a humidi-
fied chamber in the presence of primary antibodies against 
apelin/APJ (Table I). On the next day, goat anti-mouse anti-
bodies for apelin (cat. no. A11001; Thermo Fisher Scientific, 
Inc) or goat anti-rabbit antibodies for APJ (cat. no. A10520, 
Thermo Fisher Scientific, Inc) were applied overnight at 4˚C. 
After each step, sections were carefully rinsed with PBS. The 
antibodies were diluted to 1:200 in 3% BSA. Immunofluorescent 
staining was protected from light and coverslips were mounted 
with Fluoroshield mounting medium (Sigma-Aldrich; 
Merck KGaA) with 4',6-diamidino-2-phenylindole (dAPI) 
and examined with epifluorescence microscope Leica DMR. 
To quantitatively evaluate the intensity of immunofluorescent 
reaction, digital colour images were obtained using a Nikon 
coolpix 4500 Video camera (Nikon corporation) connected 
to a video capture card (PV-BT878P1; Prolink computer, Inc.).
Immunohistochemistry. To optimize immunohistochemical 
staining, paraffin sections of human placenta tissue slides 
(GTX24360; GeneTex Inc.) were immersed in 10 mM citrate 
buffer (pH 6.0) and heated in a microwave oven (2x5 min, 
700 W). Thereafter, sections were immersed sequentially 
in 3% H2O2 for 10 min at RT and normal 5% goat serum 
(Sigma-Aldrich; Merck KGaA) for 30 min that were used 
as blocking solutions. Afterwards, sections were incu-
bated overnight at 4˚C with primary antibodies against 
apelin/APJ (Table I). Next, anti-rabbit biotinylated antibody 
and avidin-biotinylated horseradish peroxidase complex 
(ABc/HRP; 1:100; Dako; Agilent Technologies, Inc.) were 
applied at RT in succession. Bound antibody was visualized 
with 0.05% dAB as a chromogenic substrate. control sections 
included omission of primary antibody and/or substitution by 
irrelevant IgG. Thereafter, sections were washed and were 
counterstained with Mayer's hematoxylin at RT for 10 sec 
and mounted using dPX mounting media (Sigma-Aldrich, 
Merck KGaA).
AlamarBlue assay. The alamarBlue® assay (cat. no. dAL1100; 
Invitrogen; Thermo Fisher Scientific, Inc.) is based on quantita-
tion of the cells' metabolic activity and is designed to measure 
the proliferation of different cell types. cellular metabolism 
induces a chemical reduction of the alamarBlue medium, i.e. 
this assay is based on the quantitative metabolic conversion of 
the blue, non‑fluorescent resazurin to pink, fluorescent reso-
rufin by living cells. AlamarBlue stock solution was aseptically 
added to the wells in amounts equal to 10% of the incubation 
volume as described in a previous study (33). The resazurin 
reduction was determined after 3 h incubation with alamarBlue 
by measuring the absorbance at 570 and 600 nm wavelengths 
using a FLUORO reader (BioTek Instruments, Inc.).
Cell Counting Kit‑8. cell counting Kit-8 (ccK-8; cat. 
no. 96992; Sigma Aldrich; Merck KGaA) allows sensitive 
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colorimetric assays for the determination of cell prolif-
eration. Highly water‑soluble tetrazolium salt, CCK‑8, 
is reduced by dehydrogenase activities in cells to give a 
yellow-coloured formazan dye, which is also soluble in the 
culture media. The amount of the formazan dye is directly 
proportional to the number of living cells. After treating 
cells with apelin, 10 µl ccK-8 solution was added and the 
plate was further incubated for 4 h. Then, the absorbance at 
450 nm wavelength was measured using an ELISA reader 
(BioTek Instruments, Inc.).
Flow cytometry. Before staining with propidium iodide (PI), 
the cells were washed twice in 1 ml of PBS, then the cell 
pellet was resuspended in 300 µl of the PI/RNase staining 
buffer (Bd Biosciences; Becton, dickinson and company) 
and incubated for 30 min in the dark at RT. The red fluores-
cence of PI was measured by FACSCalibur flow cytometer 
(Becton, dickinson and company). A total of 10,000 cells 
were examined per sample. The percentage of cell population 
in each cell cycle phase (G0/G1, S and G2/M) was calculated 
from dNA content histograms using the WinMdI 2.8 Software 
(The Scripps Research Institute).
Statistical analysis. All experimental data were expressed as 
the mean ± standard error of the mean of three independent 
experiments (n=3). distribution of normality was checked by 
Shapiro-Wilk test. A one-way or two-way analysis of variance, 
followed by Tukey's test (GraphPad Prism 5 Software, Inc.), 
was used to determine any difference between treatments 
with apelin and control. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Expression of apelin/APJ in human trophoblastic cells. The 
expression (mRNA and protein) of apelin and its receptor, 
APJ, were studied in cytotrophoblast JEG-3 and syncytiotro-
phoblast BeWo cells to compare their expression in both cell 
lines. Using quantitative PcR, it was demonstrated that mRNA 
expression of apelin was 5-fold higher in JEG-3 compared 
with BeWo cells (5.518 vs. 0.002, respectively), while mRNA 
expression of APJ was at the same level in both placental cells 
(P<0.05; Fig. 1A). Additionally, the present study observed 
that in JEG-3 cells, apelin expression was increased compared 
with APJ, while in BeWo cells, APJ expression was higher 
than apelin. Immunoblotting results confirmed these data 
(P<0.05; Fig. 1B). Immunocytochemical analyses revealed a 
strong cytoplasmic signal for apelin in JEG-3 cells. On the 
other hand, BeWo cells exhibited a weak punctuate signal for 
apelin in the cell cytoplasm. A moderate immunosignal for 
APJ was revealed in the cell cytoplasm of both placental cell 
lines. Occasionally in BeWo cells, a strong signal was located 
in the perinuclear area (Fig. 1c).
To confirm the results from immunocytochemical studies 
in the cell lines apelin/APJ expression was analysed in the 
human placenta slides. It was observed that both apelin and 
the presence of APJ was revealed, however the signal inten-
sity was dependent on the type of placental cell/structure. In 
detail, a strong signal for apelin was visible in the cytoplasm 
of endothelial lining of blood capillaries (Fig. 2A) and in the 
maternal blood (Fig. 2B and c), while cells of the placental 
artery exhibited a moderate intensity of the apelin signal 
(Fig. 2E). A moderate to weak signal intensity for APJ was 
Table I. Antibodies used for western blotting and immunofluorescence.
Antibody Host species Vendor/cat. no. Dilution
Apelin Mouse Santa Cruz Biotechnology, Inc./sc‑293441  1:50 (IHC), 1:200 (WB)
APJ Rabbit Santa Cruz Biotechnology, Inc./sc‑33823 1:100 (IHC), 1:200 (WB)
cyclin d Rabbit cST/2978 1:1,000 (WB)
cyclin E Mouse Abcam/ab3927 1:500 (WB)
cyclin A Mouse  cST/4656 1:2,000 (WB)
cyclin B Rabbit cST/4138 1:1,000 (WB)
Phospho-ERK1/2 Rabbit cST/9101 1:1,000 (WB)
Total-ERK1/2 Rabbit cST/9102 1:1,000 (WB)
Phospho-Akt Rabbit  cST/9271 1:1,000 (WB)
Total-Akt Rabbit cST/9272 1:1,000 (WB)
Phospho-Stat3 Rabbit cST/9131 1:1,000 (WB)
Total-Stat3 Rabbit cST/4904  1:2,000 (WB)
Phospho-AMPKα Rabbit Thermo Fisher Scientific, Inc./PA5‑17831 1:1,000 (WB)
Total-AMPKα Rabbit Thermo Fisher Scientific, Inc.//PA5‑17398 1:1,000 (WB)
β-actin Mouse Sigma-Aldrich; Merck KGaA/A5316  1:3,000 (WB)
Secondary Anti‑rabbit CST/7074 1:500 (IHC), 1:1,000 (WB)
Secondary Anti‑mouse  CST/7076 1:500 (IHC), 1:1,000 (WB)
CST, Cell Signalling Technology, Inc.; WB, western blotting; IHC, immunofluorescence or immunohistochemistry; ERK, extracellular 
signal-regulated kinases; Akt, protein kinase B; AMPKα, 5'-monophosphate-activated protein kinase α; Stat3, signal transducer and activator 
of transcription 3.
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demonstrated in the cytoplasm of epithelial cells of vesicles 
and mesenchymal cells of the Whartons jelly (Fig. 2F), 
but only a few cells of the placental artery exhibited signal 
(Fig. 2G). A strong signal for APJ was seen in cells of the 
syncytiotrophoblast (Fig. 2H). No positive signals were found 
when tissues were incubated with omission of primary anti-
bodies (Fig. 2d and I).
Dose‑ and time‑dependent effect of apelin on trophoblastic 
cell proliferation. Based on the results showing higher expres-
sion of apelin in the cytotrophoblast, which represent the 
proliferative population inside placental villi, it was decided to 
study the direct role of apelin on human placenta cells prolif-
eration. The present study showed that in JEG-3 cells, apelin 
significantly increased cell proliferation after 24 h at 0.02, 0.2, 
2.0 and 20 ng/ml doses, after 48 h at 0.2 and 2.0 ng/ml doses 
and after 72 h at 0.02 ng/ml dose (P<0.05, P<0.01 and P<0.001, 
respectively; Fig. 3A). In BeWo cells, it was also observed that 
apelin increased cell proliferation after 24 h at 0.02, 0.2 and 
2.0 ng/ml doses, after 48 h at 0.2, 2.0 and 20 ng/ml doses 
and after 72 h at 2.0 and 20 ng/ml doses (P<0.05, P<0.05 and 
P<0.001, respectively; Fig. 3B).
To confirm the current findings, a CCK‑8 assay was used 
as a second method to measure cell proliferation. The present 
study showed that in JEG-3 during 24 and 48 h incubation, 
apelin at 0.2 and 2.0 ng/ml and during 72 h at 2 ng/ml had 
a significant stimulatory effect on cell proliferation (P<0.05; 
Fig. 3c), while in BeWo, after 24 and 48 h at 0.2 ng/ml and 
after 48 and 72 h at 2.0 ng/ml of apelin, cell proliferation was 
increased (P<0.01; Fig. 3d).
Figure 1. Expression and immunolocalisation of apelin and APJ in JEG‑3 and BeWo cells. (A) mRNA (B) protein expression (C) immunofluorescence labelling. 
Different letters indicate significant differences at P<0.05 between both cell lines and apelin/APJ expression. DAPI, 4',6‑diamidino‑2‑phenylindole.
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Figure 3. dose- and time-dependent effect of recombinant human apelin-13 on JEG-3 and BeWo cell proliferation. cell proliferation was measurement by 
(A) Alamar Blue in JEG-3 and (B) BeWo cells and (c) cell counting Kit-8 in JEG-3 and in (d) BeWo cells. The results are expressed as the mean ± standard 
error of the mean of three independent cultures. Statistical analysis was carried out using one-way analysis of variance, followed by Tukey's test. *P<0.05, 
**P<0.01 and ***P<0.001 vs. the control within the same time of incubation. RFU, relative fluorescent unit.
Figure 2. Immunolocalisation of apelin in human placenta tissue. Localisation of the apelin in endothelial lining of blood capillaries (red arrows; A), 
maternal blood (asterisks; B and c), placental artery (yellow arrows; E) and APJ in epithelial cells of vesicles and mesenchymal cells of the Whartons jelly 
(red arrows; F), in a few cells of the placental artery (yellow arrows; G), syncytiotrophoblast (black arrows, H). Immunohistochemistry was performed on 
normal human placenta slides. No positive signals were found when tissues were incubated without the primary antibodies (d and I).
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Effect of apelin on the cell cycle in human trophoblastic cells. 
To further confirm the influence of apelin on placental cell 
proliferation, the action of apelin on cell cycle distribution 
was investigated. In both trophoblastic JEG-3 and BeWo cells 
it was observed that apelin at dose 2.0 ng/ml significantly 
increased the percentage of cells in G2/M phase of cell cycle 
after 24 and 48 h of incubation (P<0.05; Fig. 4).
Effect of apelin on protein expression of cyclins in human 
trophoblastic BeWo cells. It is well established that cyclins func-
tion as regulators of proliferation-related cell cycle progression. 
Therefore, in the present study, the effect of apelin on protein 
expression of cyclins d, E, A and B in human trophoblastic 
BeWo cells was studied. Apelin at both doses, 0.2 and 2.0 
ng/ml significantly increased cyclin D protein expression after 
48 and 72 h incubation (*P<0.05 and **P<0.01; Fig. 5A and B). 
It was also observed that apelin increased cyclins E, A and 
B protein expression after 72 h of cell incubation at 0.2 and 
2.0 ng/ml for cyclin E, and 2.0 ng/ml for cyclins A and B 
(*P<0.05 and **P<0.01; Fig. 5A and B). Analysis of cyclins blots 
showed that cyclin E can be detected as a doublet of 50 kda and 
a single band of 42 kda, as described in datasheet of producer 
antibodies (Abcam). Moreover, in cyclin B a molecular weight 
shift was observed among bands, suggesting the possibility of 
posttranslational modification in the proteins.
Molecular mechanism of apelin action on human tropho‑
blastic BeWo cell proliferation. Apelin is known to activate 
various signalling pathways in different cell types (31-33). 
Therefore, the effect of apelin (2.0 ng/ml) on ERK1/2, 
PI3K/Akt, JAK/Stat3 and AMPKα was investigated over 
different incubation periods. These pathways were focused 
on as they have previously been shown to be involved in regu-
lation of cell proliferation (28-30). Apelin has a stimulatory 
effect on the phosphorylation of kinase p42 of ERK1/2 after 
30 min, Akt after 1 min and Stat3 after 1, 5 and 45 min of incu-
bation (P<0.05; Fig. 6A and B). Moreover, AMPKα activation 
was increased from 1 to 45 min and 90 min of incubation with 
apelin. Kinase inhibitors Pd098059, AG490 and compound c 
as well as ML221 resulted in a reversal of apelin-stimulated 
cell proliferation to control levels, except inhibitor LY294002 
(Fig. 6c).
Discussion
Apelin is a pleiotropic peptide, but its major action relates 
to energy metabolism, cardiovascular function, body fluid 
homeostasis and the last study also documented female repro-
duction. Previously published studies indicate that apelin is 
involved in pregnancy by i) regulation of blood pressure and 
angiogenesis in the preeclampsia pathophysiology; ii) effects 
on plasma volume expansion in foetal growth; and iii) regu-
lation of glucose metabolism in the gestational diabetes 
pathophysiology (21,23,25). However, there are no data 
regarding the direct effects of apelin in trophoblast cell prolif-
eration or the cell cycle. In the present study, the expression 
Figure 4. Effect of recombinant human apelin-13 on JEG-3 and BeWo cell cycle. Representative histograms of the cell cycle and the percentage of propidium 
iodide stained (A) JEG-3 and (B) BeWo cells in the particular phases of cell cycle. The results are expressed as the mean ± standard error of the mean of 
three independent cultures. Statistical analysis was carried out using one-way analysis of variance, followed by Tukey's test. *P<0.05 vs. G2/M phase of the 
corresponding control.
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and immunolocalization of the apelinergic system was first 
checked in both human trophoblastic cell lines syncytiotro-
phoblast BeWo and cytotrophoblast JEG-3 as well as in human 
placenta slides. Both these cells lines maintained numerous 
characteristics of human trophoblastic cells and have been 
widely used to study cellular and molecular signalling in 
the placenta (36-38). Additionally, the molecular mechanism 
involved in the human recombinant apelin-13 action on cell 
proliferation was investigated.
The results of the present study clearly demonstrated 
that apelin expression was higher in cytotrophoblast JEG-3 
cells than syncytiotrophoblast BeWo cells, while APJ was 
at the same level in both placental cell lines. Moreover, in 
JEG-3 cells, apelin expression was increased compared with 
APJ, while in BeWo cells, higher expression of APJ than 
apelin was noted. These results agree with previous data by 
cobellis et al (3), showing that the level of apelin expression 
in the human placenta was much higher in cytotrophoblast 
cells compared to syncytiotrophoblast. cytotrophoblast are 
mononucleated cells that represent the proliferative popula-
tion inside placental villi; this particular localization suggests 
the direct role of apelin/APJ on human placenta cells prolif-
eration. Additionally, high cytoplasmic and/or membrane 
apelin localisation was also described in JEG-3 cells, while 
BeWo cells exhibited weaker apelin signal in the cell cyto-
plasm. Immunolocalization of APJ revealed a moderate 
signal in the cell cytoplasm in both placental cells, while a 
weaker signal was observed within the nuclei. Additionally, 
Figure 5. Effect of recombinant human apelin-13 on cyclins protein expression by (A) western blotting and (B) densitometry analysis. The results are expressed 
as the mean ± standard error of the mean of three independent cultures. Statistical analysis was carried out using one-way analysis of variance, followed by 
Tukey's test. *P<0.05, **P<0.01 vs. the control within the same time of incubation.
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Figure 6. Molecular mechanism of mitogenic action of apelin-13. Kinases p-ERK1/2, total ERK, p-Akt, total Akt, p-Stat3, total-Stat3, p-AMPKα and total 
AMPKα were detected by (A) western blotting and (B) densitometry analysis. cells were pre-treated for 1 h with selective inhibitors of ERK 1/2, Akt, Stat3 
and AMPKα kinases (Pd98059, LY294002 and AG490 compound c respectively) and APJ inhibitor (ML221), after which apelin (2 ng/ml) was added for 72 h 
and cell proliferation was studied (c). The results are expressed as the mean ± standard error of the mean of three independent cultures. Statistical analysis was 
carried out using one-way analysis of variance *P<0.05, **P<0.01, ***P<0.001 vs. the control or two-way analysis of variance, followed by Tukey's test. different 
letters indicate significant differences at P<0.05. RFU, relative fluorescent unit; p, phosphorylated; ERK, extracellular signal regulated kinase; Akt, protein 
kinase B; Stat3, signal transducer and activator of transcription 3; AMPKα, 5'-monophosphate-activated protein kinase α.
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immunohistochemistry on human placental slides showed a 
strong signal for apelin in the cytoplasm of the endothelial 
lining of blood capillaries and in maternal blood, while cells 
of the placental artery exhibited a moderate intensity of the 
apelin signal. A moderate to weak signal intensity for APJ 
was located in the cytoplasm of epithelial cells of vesicles and 
mesenchymal cells of the Whartons jelly and a strong signal 
for APJ was observed in cells of the syncytiotrophoblast. 
The results of the present study demonstrating expression of 
apelin/APJ in endothelial and epithelial cells of vesicles were 
confirmed by a previous study documenting apelin expression 
in the vascular endothelial cells lining blood vessels of the 
human heart, rat blood vessels and a high level in endothelial 
cells of other vessels (39). In the light of these observations 
cobellis et al (3) presented the hypothesis that apelin expressed 
by endothelial cells, acting on vascular smooth muscle in a 
paracrine fashion has a vasoconstrictor potential and can be a 
biochemical marker in preeclampsia, which is characterized by 
endothelial dysfunction. The current results partly confirmed 
this hypothesis. To summarize the first part of the present 
study, the expression of both components (ligand and receptor) 
of the apelin signalling system provides the opportunity for 
analysis of the direct role of apelin in human placenta cells.
Since the cytotrophoblast cells represent the proliferative 
population inside placental villi, this particular localisation 
led the present study to investigate a possible role for apelin 
in the regulation of proliferation, as previously demonstrated 
on other models like gastric epithelial cells (40) or umbilical 
endothelial cells (41). The present study observed that 
apelin increased placental cell proliferation. This effect was 
observed with human recombinant apelin-13 concentrations 
ranging from 0.02 to 20 ng/ml, whereas the literature data 
documented that apelin is significantly decreased in pregnant 
women (4.45-8.7 ng/ml vs. 5.0-9.3 ng/ml in control) (42). In the 
present study, apelin-13 was used because data presented by 
Yamaleyeva et al (21) documented that apelin-13, (Pyr1)-apelin 
and possibly oxidised apelin-12 were the major forms in both 
normal and preeclamptic chorionic villi. In fact, apelin has 
been shown to exhibit mitogenic action in numerous cell types, 
including cardiomyoblast cells (43), ovarian cells (33), vascular 
smooth muscle cells (VSMc) (44) and endothelial cells (45).
cell cycle analysis was performed to determine the mecha-
nisms underlying the proliferative effects of apelin on placenta 
cells. The present data indicate the important role of apelin in 
placenta cell cycle progression. Apelin stimulates the transition 
to G2/M phase that is required for cell division and, as shown 
by further analysis, cyclins were involved in the observed apelin 
effect. Therefore, modulation of the cell cycle and expression of 
cyclins by apelin is strictly connected with its biological activity. 
It is well known that progression through the G2/M is connected 
with the expression of cyclin B, among other proteins. An 
enhancement of cyclins d, E, A and B in response to human 
recombinant apelin-13 was found. cyclins and cyclin-dependent 
kinases are subunits of cell cycle-dependent protein kinases that 
regulate key events during the progression of the cell cycle (46). 
Moreover, the level of cyclin proteins is selectively expressed in 
different phases of the cell cycle, for example the rise in cyclin d 
is followed later during G1 by the appearance of cyclin E, which 
rapidly disappears towards the beginning of dNA synthesis 
(S phase) (47). Mitogenic signals (e.g., growth factors and serum 
compounds) that stimulate cell progress through G1 coincide 
with an increased expression of cyclin d. The present study 
found enhancement of cyclin d expression in response to apelin 
at the 48 time point. Therefore, earlier modulation of cyclin d 
by apelin facilitated cell cycle progression. It is known that after 
progression through the cyclin d-dependent portion of the cell 
cycle, cyclin E becomes activated (48) and further facilitates 
cell cycle progression through S towards G2/M phase. current 
results strongly indicate that apelin modulates cell cycle 
progression by affecting the activation of cyclins, especially 
cyclin d and E. cyclin A begins to appear towards the end of G1, 
continues to rise during the S phase and then through G2 phase 
rapidly declines as the cell progresses, while level of cyclin B 
begins to appear during the S phase. This rise continues into the 
G2 phase before rapidly falling during the mitotic phase (47). 
Therefore, apelin can enhance the cell cycle by promoting the 
switch of cells from S phase to G2/M phase. Additionally, it 
is a well-known fact that the increase in expression of the cell 
cycle machinery is a key event in regulating cell proliferation. 
Further studies are needed to understand how apelin cooperates 
with precise signalling pathways to regulate these cyclins. The 
present results agree with data of Li et al (44) indicating that 
apelin increased cell cycle progress by stimulating the expres-
sion of cyclins d1 and E in VSMc cells.
The last part of the current study focused on description of 
the molecular mechanism of apelin action in placenta cells by 
studying the effect of apelin on signalling pathways and next 
the role of APJ receptor and activation of different kinases was 
investigated. The present study showed that apelin at 2 ng/ml 
stimulated phosphorylation of kinases ERK1/2, Akt, Stat3 and 
AMPKα, but cell proliferation was reduced to control levels in 
the culture with pharmacological inhibitors of APJ receptor and 
kinases ERK1/2, Stat3 and AMPKα but not Akt. In the authors' 
preliminary studies all inhibitors of kinases ERK1/2, Akt, Stat3 
and AMPKα (Pd98059 at 10 µM, LY294002 at 10 µM, AG490 
at 50 µM and compound c at 10 µM, respectively), as well as 
inhibitor of APJ (ML221 at 10 µM) were used alone to check 
that their concentration and no effect on cell proliferation was 
observed. Previous data showed that apelin induced cell prolif-
eration by activation of different signalling pathways through 
PI3/Akt activation in rat granulosa cells (49), endothelial 
progenitor cells (50) and retinal pigment epithelial cells (30); 
or via ERK1/2 in human breast cancer cells (McF-7) (51) and 
lung adenocarcinoma (52). These observations suggest that 
the molecular mechanism of the mitogenic action of apelin 
is cell specific. Thus, a potentially new mechanism of apelin 
action can be described as follows: Apelin-induced stimula-
tion of trophoblastic cell proliferation regulates early placental 
development. As a result, the condition of the placenta directly 
indicates the well-being of the developing foetus.
In conclusion, the results of the present study noted that 
apelin is produced by trophoblastic cells and can be involved 
in the human placenta physiology. It was observed that this 
adipokine by stimulation of placenta cell proliferation via APJ 
activation and kinases ERK1/2, Stat3 and AMPKα pathways 
can be new regulator of early placental development. The limi-
tations of the study must also be acknowledged. All in vitro 
results were obtained using human placenta cell lines, so the 
structure and local microenvironment in the placenta tissue 
did not exist. To complete these results, future studies on 
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placenta explants or in vivo animals models will be necessary 
for understanding the role of apelin on placenta cells physi-
ology. For example, Van Mieghem et al (23) conducting the 
apelin studies on rats documented that maternal plasma apelin 
levels decreased in the last week of gestation due to increased 
elimination by the fetoplacental unit, however role of apelin on 
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